Medtronic (MDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT)

MDT 90.41

0.0%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas J Pittman who started this subject	11/29/2001 7:53:26 AM
From: Jack Hartmann	Read Replies (1) of 687

Morningstar on MDT Medtronic's MDT October-quarter results, released Tuesday, show the many strengths of this diversified medical device manufacturer, but are not enough to change our cautious stance on the stock. Precharge earnings were $0.29 per share, up 16% from the year-ago quarter, beating analysts' estimates by a penny. We continue to forecast double-digit sales and earnings growth, based in part on improved prospects for Medtronic's heart device segment. Moreover, the company's MiniMed acquisition places it squarely at the forefront of novel diabetes treatment devices, which increased sales at a segment-leading 30% compared with a year ago. Travis Pascavis Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next